D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
Scott Gottlieb has a lot of thoughts on CBD
When I chatted with the former FDA commissioner about the agency’s efforts to regulate CBD, one thing was crystal clear: Gottlieb probably isn’t going to be offered a job as the head of the CBD lobby any time soon.
“There’s no science to demonstrate that putting it in the food supply has any medicinal value, let alone [to] support that it’s safe. People are just doing it,” Gottlieb told me.
Our chat came just after I published a story about the FDA’s quest (or perhaps, its struggle) to regulate CBD, or cannabidiol, in dietary supplements.
Gottlieb, like any good (former) regulator, also emphasized that he believes there’s likely a “pharmaceutical opportunity here,” and listed neurological and neuromuscular disorders
... read more at: https://www.statnews.com/2019/05/21/dc-diagnosis-gottlieb-cbd/